A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Buod ng balita
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Subaybayan ang mga pinakabagong balita mula sa mapagkakatiwalaang publisher na may maiikling buod. Buksan ang orihinal na link para sa detalye.